Fosamax Articles
IVAX tentative FDA alendronate approval
5 August 2002
Actonel cuts first fracture rate 75%
24 June 2002
Five key products continue to drive Merck & Co sales in 2001
28 January 2002
Merck points to robust pipeline despite near-term profits warning
12 December 2001
Roche, GSK link up on osteoporosis drug
7 December 2001
Merck & Co turnover up 13% but Vioxx sales are slowing down
19 October 2001
Merck & Co sales up 13% for 3rd qtr
18 October 2001
Merck sues Teva over generic alendronate
8 October 2001
PDI's stock leaps following deal with Lilly
5 October 2001
Barr gets tentative OK for 10mg Prozac tabs
6 September 2001
Japan pharma stocks in week to August 27
29 August 2001
Merck & Co changes web as FDA complains
3 August 2001
Five drugs push Merck & Co sales up 25%
23 July 2001
Stock Commentary - Tokyo
28 June 2001
New data presented at ENDO 2001
27 June 2001
Japan pharma stock market, week to June 25
27 June 2001
Nu-lotan driving sales at Banyu
8 June 2001
Japan pharma stock market week to May 21
23 May 2001
Akzo seeks better US labeling for Xyvion
27 April 2001
Merck & Co sales leap 28%; EPS up 13%
23 April 2001
Lilly seeks US approval for osteoporosis drug
8 January 2001
Osteoporosis market "to more than triple"
23 November 2000
Banyu sees delay for Fosamax in Japan
17 November 2000
Stock Commentary Tokyo
5 October 2000
Merck & Co wins male label for Fosamax
5 October 2000
Merck & Co's once-weekly Fosamax show placebo-comparable ulcer effect
28 September 2000
Aventis/P&G claim superiority of Actonel over Merck & Co's Fosamax
25 September 2000
Fosamax shown to be effective in men
1 September 2000
Merck & Co posts strong sales growth
25 July 2000
Media criticized over new drug reporting
5 June 2000
Merck & Co's Fosamax effective after seven years
18 May 2000
Actonel cleared for osteoporosis in USA
18 April 2000
Banyu aims to be among Japan's top five
21 March 2000
Merck & Co goes once-weekly with osteoporosis drug Fosamax
24 November 1999
HMR/P&G gain first approval for risedronate, in Sweden
14 October 1999
Raloxifene approval hots up osteoporosis treatment market
11 October 1999
Eli Lilly's Evista shows efficacy in osteoporosis treatment
19 August 1999
Merck's Fosamax OKed for expanded use
24 June 1999
Merck and Novartis battle over drug trial
17 June 1999
Osteoporosis Drug Evista Halves Breast Cancer Risk
16 December 1998
Osteoporosis Drug Evista Halves Breast Cancer Risk
14 December 1998
Evista Shows Promise In Spine Fractures
8 December 1998
First Launch Of Actonel For Paget's
21 October 1998
Studies Reveal Side Effect Burden With Fosamax
15 October 1998
Novartis' Miacalcic Nasal Spray - Four-Year Results
17 September 1998
Osteoporosis, A Health Burden For Europe
1 July 1998
Phase II Levormeloxifene Data Raise Concerns
25 June 1998
Analysts Forecast Bright Outlook For US Majors
8 April 1998
Risedronate Cleared By FDA For Paget's
8 April 1998
Risedronate In Osteoporosis Prevention
5 March 1998
Merck's Singulair Cleared In USA For Asthma
24 February 1998
FDA Approves Raloxifene For Osteoporosis
11 December 1997
Lilly's Evista Backed By US Panel For Osteoporosis
27 November 1997
Drug Promo Meetings "Up 61% Since 1995"
27 October 1997
US DTC Advertising Is Fastest Growing Promotional Segment
21 October 1997
Sanofi Drops Tiludronate For Osteoporosis
25 September 1997
P&G To File NDA For Actonel In 1998
17 September 1997
Fracture Rate Halved With Fosamax
17 September 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Raloxifene Data Lives Up To Expectations
12 June 1997
Merck & Co Acquires Istituto Gentili
9 June 1997
New CPAC Approvals Include Two NCEs
7 April 1997
Fosamax Cleared For Osteoporosis Prevention
10 March 1997
Lilly Forecasts Strong Sales For Prozac
27 January 1997
Alendronate In Fracture Intervention
16 December 1996
Global Branding Is A Must For Pharmaceuticals
12 August 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
FIT Women Reveal Alendronate Benefits
3 June 1996
Merck's New Drugs For Arthritis And Infections
27 May 1996
US FDA Seeks Comments On Consumer Ad Labeling
27 May 1996
11% 1st-Qtr EPS Rise From US Drug Cos
15 April 1996
Fosamax Scare On Safety Issue
1 April 1996
Fosamax In Paget's Disease
11 March 1996
Sandoz Launches Nasal Calcitonin In USA
18 December 1995
Cortecs' Oral Calcitonin Closer To Market
20 November 1995
Winners And Losers In US Medicare/Medicaid Reform
20 November 1995
Merck: Fosamax news
30 October 1995
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
